Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Obstetrics and Gynecology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1552132

This article is part of the Research TopicAdvancing HIV Treatment and Prevention for Cisgender Women: Approaches to Optimize Health OutcomesView all 7 articles

"When he is around, I'll take the PrEP, but when he is not, I will not take PrEP": Key Influences on PrEP Use Decisions among Women Attending Family Planning Clinics in Kenya Authors

Provisionally accepted
Vallery  OgelloVallery Ogello1*Kristin  Beima-SofieKristin Beima-Sofie2Sandra  UrusaroSandra Urusaro2Mercy  AwuorMercy Awuor3Annabell  DollahAnnabell Dollah3Winnie  AtienoWinnie Atieno3Cynthia  WanderaCynthia Wandera3Daniel  MatemoDaniel Matemo3Jennifer  F MortonJennifer F Morton2Kenneth  NgureKenneth Ngure4John  KinuthiaJohn Kinuthia3Kenneth  K. MugwanyaKenneth K. Mugwanya2
  • 1Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
  • 2Department of Global Health, University of Washington,, Seattle, WA, United States
  • 3Research & Programs, Kenyatta National Hospital, Nairobi, Kenya
  • 4School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

The final, formatted version of the article will be published soon.

Background: Women of childbearing age in sub-Saharan Africa (SSA) face a disproportionately high risk of HIV acquisition. Although oral PrEP has been scaled up universally for individuals at significant risk of HIV, uptake and sustained use remain suboptimal. Understanding PrEP use decisions offers insights into context-specific barriers and facilitators to its utilization. Methods: From September to November 2023, we conducted a qualitative study nested in a larger prospective, open-label clinical trial (FP-Plus). We conducted in-depth interviews (IDIs) with younger women (ages 15-24) and older women (ages ≥25) who declined, delayed, discontinued, or restarted PrEP during the study. IDIs were conducted at two FP clinics by trained Kenyan social scientists and were audio recorded, translated, and transcribed. We analyzed data using inductive and deductive thematic analysis through the lens of the theory of planned behavior (TPB), to explore experiences, beliefs, and rationale among women who made different PrEP decisions. Results: We interviewed 64 women, including 40 younger women and 24 older women, who declined, delayed, discontinued or restarted (n=16 women/category) PrEP. Women were a median age of 24 years (IQR, 23-30). Most participants (86%, 55/64) were using family planning methods, primarily injectables (42%, 23/64). PrEP discontinuation or restart was majorly influenced by changes in HIV risk dynamics. Agency and perceived HIV risk were pivotal factors in PrEP use decisions, shaping participants' ability to practice effective prevention adherence (TPB: perceived behavioral control). Women who declined PrEP cited a lack of autonomy, partner influence, and insufficient information (TPB: social and subjective norms). Low self-efficacy influenced decisions to delay or decline PrEP (TPB: behavioral beliefs and attitudes). In addition, challenges with PrEP pill size, taste, and texture were perceived as barriers to swallowing pills among all groups of women. Participants expressed a preference for alternative PrEP formulations, such as injectable PrEP, due to perceived ease of use, privacy, and potential to support adherence. Conclusion: PrEP discontinuation and restart cycles largely reflected changes in HIV risk. Women who decline or delay PrEP may benefit from personalized support to improve their autonomy, recognizing that HIV risk persists during periods of PrEP delay.

Keywords: hiv prevention, PrEP use decisions, Family planning clinics, implementation science, Women of childbearing age

Received: 27 Dec 2024; Accepted: 09 Jun 2025.

Copyright: © 2025 Ogello, Beima-Sofie, Urusaro, Awuor, Dollah, Atieno, Wandera, Matemo, Morton, Ngure, Kinuthia and Mugwanya. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Vallery Ogello, Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.